FDG-PET response and outcome from anti-PD-1 therapy in
21 août 2018 Background: Immune checkpoint inhibitor therapy has resulted in impressive and durable clinical activity for many cancers including melanoma ...
Mélanome — Thérapeutique par les médications : anticorps anti
anticorps anti-CTLA-4 et anti-PD1. Mots-Clés : Mélanome. Immunothérapie. Récepteur-1 de mort cellulaire pro- grammée. Anticorps. Drug therapy of melanoma:
pages
Genomic and Transcriptomic Features of Response to Anti-PD-1
High mutational loads are associated with improved survival in melanoma patients but are not predictive of response to anti-. PD-1 therapy suggesting that
S ( ) X
Anti-PD-1 therapy in patients with advanced melanoma and
29 sept. 2016 melanoma and preexisting autoimmune disorders or ... At the time of commencement of anti-PD-1 antibody therapy.
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a
6 juin 2020 Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Y. Nakamura1* K. Namikawa2
Management of early melanoma recurrence despite adjuvant anti
6 mai 2020 Therefore adjuvant PD1 therapy is a new standard of care for high-risk resected melanoma
L'immunothérapie par anticorps anti-CTLA-4 et anti-PD1 Le
Two phases III have demonstrated that ipilimumab treatment is effective on overall survival patients with metastatic melanoma. This treatment is now authorized
L’immunothérapie par anticorps anti CTLA et anti PD
Intratumoral Activity of the CXCR3 Chemokine System Is Required
13 mai 2019 in plasma of melanoma patients were an indicator ... the efficacy of anti-PD-1 therapy in mouse tumor models.
S ( )
Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced
Methods: This was a single institution cohort analysis in patients treated with anti-PD-1 right after BRAFi ipilimumab
Genomic and Transcriptomic Features of Response to Anti-PD-1
24 mars 2016 PD-1 immune checkpoint blockade therapy induces a high rate of anti-melanoma response and provides unprecedented clinical benefits (Hamid et al.